Identifying and Managing Adverse Effects and Drug-Drug Interactions in Patients With RET-mutated Thyroid Cancers
Last Updated: Thursday, May 16, 2024
Juna Jovani, PharmD, BCPS, BCOP, and Alexander Robinweiler, PA-C, MCHS, discuss the pharmacist’s perspective on the use of pralsetinib and selpercatinib with RET-mutated thyroid cancers and ways to reduce side effects, including hypertension. Juna and Alex share information on when to dose reduce and review the baseline testing that may be needed prior to starting medications.
Meet the faculty
![](/media/gweh4ygw/jovani_juna_2-09.jpg)
Juna Jovani
PharmD, BCPS, BCOP
The US Oncology Network – McKesson
Juna Jovani is a senior clinical pharmacist, responsible for the oversight and modification of pharmacotherapy for adult oncology patients in the community setting, specializing in breast oncology with sub-specialties in thoracic, head and neck, central nervous system, genitourinary, cutaneous, and gynecologic oncology. Juna participates in the development, implementation, and ongoing review of pharmacy policies and procedures within the ClinReview team.
![](/media/zhopfrcm/robinweiler_alex_2-09.png)
Alex Robinweiler
PA-C, MCHS
Fred Hutch Cancer Center, Teaching Associate, University of Washington School of Medicine
Alex Robinweiler is a physician assistant at Fred Hutch and a teaching associate at the University of Washington. Before joining Fred Hutch at Overlake Cancer Center, he worked in family medicine and urgent care for several years. His area of clinical practice is working with patients in general medical oncology, benign and malignant hematology, at a community oncology site.
References
- Wirth, L. J., Sherman, E., Robinson, et al. (2020). Efficacy of selpercatinib in RET-altered thyroid cancers. The New England Journal of Medicine, 383(9), 825–835. https://doi.org/10.1056/NEJMoa2005651